The tolerability profile aligns with the GLP‐1 class, with gastrointestinal events predominating and a low risk of clinically important hypoglycemia; biliary events may be more likely at higher doses, while pancreatitis risk has not been clearly elevated. Here, GLP1R is linked to Hypoglycemia.